CDC Avails $262M to New Network Aimed at Responding to Future Disease Outbreaks

September 29, 2023 13:50:57

The Centers for Disease Control (CDC) will provide $262 million to fund the development of a new disease outbreak response network. Per the announcement, recipients will receive grants from the pool of more than  $250 million to establish America’s first-ever response network in anticipation of future disease outbreaks. The grants will fund the development and implementation of new tools meant to detect and mitigate public health emergencies such as pandemics and disease outbreaks in the future.

According to a statement from the CDC, it will distribute funds for the development of the Outbreak Analytics and Disease Modeling Network (OADMN) to 13 state health departments, private healthcare providers, academic institutions and tribal organizations over a five-year period.

Passed in the wake of the coronavirus pandemic, the 2021 America Rescue Plan instructed the CDC to form a Center for Forecasting and Outbreak Analytics (CFA) to create advanced infectious disease analytical tools and models as well as modernize America’s surveillance and data systems. Consequently, the CDA launched the CFA in April 2022 with an initial funding of $26 million and a focus on promoting health equity, building a competent workforce, and developing yearly models of the SARS-CoV-2 omicron variant.

CFA director Dylan George noted in a press release that the agency’s collaboration with partners in the private, public and academic sectors in the past year has significantly aided in the advancement of disease forecasting science and led to major improvements in the nation’s disease outbreak response capabilities.

The Center for Forecasting and Outbreak Analytics was also responsible for choosing the 13 recipients tasked with building a new outbreak response system to help prevent future pandemics. These institutions will have to carry out a “landscape analysis” to spot gaps and find disease modeling and outbreak analytic needs, develop pilot technologies to optimize public health surveillance, prepare for infectious disease outbreaks such as the coronavirus pandemic and respond to these outbreaks when they arise.

George explained that this experience would allow the institutions to establish a national network that would allow the country to respond to future disease outbreaks more effectively and prevent them from snowballing into pandemics.

The 13 institutions are the University of Texas at Austin, Clemson University, Carnegie Mellon University, Emory University, University of Michigan School of Public Health, University of California in San Diego, International Responder Systems, University of Minnesota, University of Carolina at Chapel Hill, Kaiser Permanente Southern California, University of Utah, Northeastern University and Johns Hopkins University.

As the CDC works to establish a disease response network, private actors such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are hard at work developing novel immunotherapies targeting infectious diseases so that those infections don’t take a heavy toll on communities and the economy.

NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN